Last reviewed · How we verify
Pre-Op (HEXACHLOROPHENE)
HEXACHLOROPHENE (Pre-Op), marketed by Davis And Geck, is an antiseptic agent used primarily for pre-operative skin preparation. Its key strength lies in its mechanism of action, which effectively disrupts the cell membranes of bacteria and other microorganisms, leading to their death. The primary risk is the upcoming key patent expiry in 2028, which could lead to increased competition from generic alternatives.
At a glance
| Generic name | HEXACHLOROPHENE |
|---|---|
| Sponsor | Davis And Geck |
| Drug class | Antiseptic |
| Target | N-acyl-phosphatidylethanolamine-hydrolyzing phospholipase D, 78 kDa glucose-regulated protein, Adenosine receptor A3 |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
| First approval | 1949 |
Approved indications
Common side effects
Key clinical trials
- A Prospective Cohort Pilot Study of the Clinical and Molecular Epidemiology of Staphylococcus Aureus in Pregnant Women at the Time of Group B Streptococcal Screening in a Large Urban Medical Center in Chicago, IL USA (NA)
- Prospective Study of Methicillin-Resistant Staphylococcus Aureus (MRSA) Among HIV-Infected Persons (NA)
- A Prospective Trial of Nasal Mupirocin, Hexachlorophene Body Wash, and Systemic Antibiotics for Prevention of Recurrent Methicillin Resistant Staphylococcus Aureus Infections (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |